Mallinckrodt – The Volatility Continues?
Although Mallinckrodt’s bonds are trading at a significant discount to par, we recommend investors remain side-lined given our assessment of the...
696 Views
Antitrust Insights for Smaller US Mergers
Non-Reportable ≠ Non-ReviewableAcquisitions of U.S. companies that fall below the $80.8 million Hart-Scott-Rodino (HSR) reporting threshold may...
417 Views
Allergan's Wide Moat Supports Industry-Leading Growth and Profit
Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook. We anticipate high-single-digit growth for...
389 Views
Valeant & Philidor Bezzle: Clarity Will Take Awhile
It has been two weeks since I published The Valeant Bezzle Saga Continues: Confidence Game? and four weeks since VALEANT & Philidor Bezzle: On...
1.2k Views